ERBB2 and neoplasm: This signature was able to predict HER2‐positive tumours with 95% accuracy (AUC = 0.96) in the cross‐validation set and 83% (AUC = 0.82) in the external test cohort (Figure 8), in comparison to ERBB2 mRNA (AUC = 0.80).